TX-LIGHTBEAM-HEALTH
9.8.2021 20:33:22 CEST | Business Wire | Press release
Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, is proud to announce their partnership with Ambry Genetics, a Konica Minolta Precision Medicine (KMPM) company. The partnership provides precision genetic testing data within the Lightbeam application to help organizations predict increased risk for common cancers and chronic conditions within patient populations.
According to the Centers for Disease Control and Prevention , 1.6 million people are diagnosed with cancer each year in the United States. The Ambry Genetics-Lightbeam partnership is expected to reduce this burden with tools for early detection and prevention by allowing providers to quickly identify, assess, and engage patients who meet specific risk factors. As the body of genetic evidence expands, so too will the value brought to mutual clients of Lightbeam and Ambry Genetics.
The CARE (Comprehensive, Assessment, Risk and Education) Program™ will integrate into the Lightbeam Platform, providing an additional clinical data stream for clients to enhance Lightbeam’s proprietary Ability-to-Impact (ATI) risk score. Genetic risk information is critical because it informs personalized patient care to include preventive surgeries, increased cancer screening, and in some cases, targeted therapies.
“At Lightbeam, part of our vision is to help organizations transform care delivery from being reactive to proactive,” said Pat Cline, CEO of Lightbeam. “We believe this partnership with Ambry Genetics will positively impact lives with its ability to indicate whether a person is high-risk for cancer or other diseases. In combination with our industry-leading analytics platform, Ambry’s genetic data further enhances how Lightbeam clients can improve quality, reduce costs, and positively impact outcomes for the populations they serve.”
“Today, only a fraction of individuals with a hereditary predisposition to disease are tested,” said Rob Guigley, Chief Commercial Officer, Ambry Genetics. “Our partnership with Lightbeam intends to bring greater access to the community and empower patients and providers to make informed preventative decisions that can improve health care and management. The potential impact of this relationship is significant for patients, providers, and payors.”
For more information on this innovative partnership, visit the Lightbeam Health booth , #2060 in the Sands Expo, at HIMSS21 in Las Vegas, Nevada, from August 9-13, 2021.
About AMBRY GENETICS ®
Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.
About Lightbeam Health Solutions
Lightbeam Health Solutions delivers a revolutionary model for managing patient populations and associated risk. Lightbeam’s vision is to bring health data into the light through the use of analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Lightbeam’s platform facilitates end-to-end population health management for ACOs, payers, provider groups, health systems, and other healthcare organizations aspiring to provide superior care at a lower cost. For more information, visit www.lightbeamhealth.com , and follow Lightbeam on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005688/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Poland's Galaxy Systemy Informatyczne Becomes First Private Enterprise to Buy Quantum Computer from IQM7.4.2026 15:00:00 CEST | Press release
IQM will deliver and install the 54-qubit quantum computer at Galaxy in the fourth quarter of 2026. The deployment builds Galaxy’s quantum capabilities, supporting talent development and innovation across sectors, while reinforcing Poland’s growing quantum ecosystem. This will be another Radiance 54-qubit computer deployed this time in Poland by IQM, following installations at LRZ in Germany, VTT in Finland, CINECA in Italy, and CESGA in Spain, underscoring the company’s leading market position. IQM Quantum Computers, a global leader in superconducting quantum computing, today announced a commercial milestone to deploy a hybrid integrated quantum computer at GalaxySystemy Informatyczne Sp. z o.o., marking its first deployment in a private enterprise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407351934/en/ IQM Radiance quantum computer Galaxy has been implementing innovations in security, digitisation, and h
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery7.4.2026 15:00:00 CEST | Press release
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities. “Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partn
Textron Aviation Receives First Military Order for Cessna SkyCourier, Launching the Aircraft Into Global Defense Market7.4.2026 15:00:00 CEST | Press release
Belgium selects SkyCourier fleet to boost special operations airlift for troop transport, logistics, casevac and crisis response Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Belgium has selected the Cessna SkyCourier as its newest special mission aircraft, awarding an order for five multirole aircraft to support the nation’s Special Operations Forces. The selection launches the SkyCourier into the global defense market for the first time and strengthens Belgium’s airlift capability through a rugged, flexible platform built for demanding missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309292194/en/ A new ally in the air: An artist’s rendering shows a Cessna SkyCourier configured for military operations, including a special operations paint scheme and mission equipment. The aircraft was selected by Belgium Special Operations Forces. Belgium’s SkyCourier fleet will enable rapid movement
Gurobi Defines Its Role as the Technology Behind Better Decisions in the AI Era7.4.2026 15:00:00 CEST | Press release
The decision intelligence leader emphasizes the critical partnership between AI-driven insights and optimized solutions. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a renewed brand identity that reflects its role in empowering organizations to make better decisions in complex, high-stakes environments. As organizations increasingly rely on optimization to put their AI-driven insights into action, the Gurobi Optimizer is a foundational component of decision intelligence systems, where different approaches to AI—from prediction to optimization—work together to guide business outcomes. “AI has transformed how organizations generate insight, but insight alone does not drive outcomes—decisions do,” said Duke Perrucci, CEO, Gurobi. “We see optimization as the GPS for AI, enabling users to determine the best possible course of action in complex environments. Those decisions are what drive real outcomes, and we’re proud to be the technology behind
Cessna SkyCourier Strengthens Mission Versatility With New In‑Flight Operable Door Option7.4.2026 15:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced a new In-Flight Operable Door option for the passenger variant of its twin-engine, large-utility Cessna SkyCourier turboprop, expanding the aircraft’s Special Mission versatility for military, humanitarian and commercial operations. The functionality is expected to be available as a Special Mission factory-installed option in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407228562/en/ Mission flexibility starts at the Cessna SkyCourier door “An In-Flight Operable Door builds on the Cessna SkyCourier’s reputation for reliability and adaptability, reinforcing its role as a purpose-built solution for high-demand missions,” said Bob Gibbs, vice president, Special Missions Sales. “The option opens new opportunities for customers worldwide, including armed forces, smokejumpers, disaster relief groups and commercial skydiving operators.” The Cessna
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom